[2, 3] Pharmacological inhibition of TEADs by small molecules prevents growth of NF2‐null/LATS1‐fusion mesothelioma, schwannoma and meningioma.[4, 5]YAP1 amplification/fusion has been frequently found in solid tumors such as breast cancers and hepatocellular carcinomas.[6, 7] Dysregulation of YAP/TEAD is also frequently correlated with chemoresistance to therapeutic drugs which shed light on combination therapy. Here, YAP1 is linked to breast carcinoma.